Bruce Cree, MD
Enriched profileProfessor of Clinical Neurology; George A. Zimmermann Endowed Professor in Multiple Sclerosis, UCSF Department of Neurology · University of California, San Francisco (UCSF)
Bruce Cree is Professor of Clinical Neurology; George A. Zimmermann Endowed Professor in Multiple Sclerosis, UCSF Department of Neurology at University of California, San Francisco (UCSF). OpenAlex indexes 489 publications with 31,011 citations (h-index 85); ClinicalTrials.gov lists 4 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Neurology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Bruce Cree, M.D., is Professor of Clinical Neurology at University of California, San Francisco (UCSF), Department of Neurology / UCSF Weill Institute for Neurosciences. The public record shows 489 publications with 31,011 citations (h-index 85), centered on Multiple Sclerosis Research Studies, Peripheral Neuropathies and Disorders, Sphingolipid Metabolism and Signaling. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 17 companies, 1 NIH-funded awards (2005–2009).
- Most recent indexed publication: 2026 · Annals of neurology
- Top research focus: Multiple Sclerosis Research Studies
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 17 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 63 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 230.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset
Sponsor: University of California, San Francisco
- Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Sponsor: MedDay Pharmaceuticals SA
Industry payments
Updated 14 Oct 2026
17 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20258 payments$38,388openpaymentsdata.cms.gov ↗
- Biogen, Inc.Program year20254 payments
- TG Therapeutics, Inc.Program year20259 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
48%Gabapentinoids20.5%Gabapentin89%Pregabalin12%Part D<11 patientsPotassium Channel Blocker13.2%Dalfampridine Er100%Part D≥14 patients+ 4 more classes in this area
Cancer & immunology
21.7%CD20-directed Cytolytic Antibody8.7%Kesimpta Pen100%Part D<11 patientsOther immunosuppressants5.8%Dimethyl Fumarate56%Tecfidera44%Part D<11 patients+ 2 more classes in this area
Genitourinary & hormones
12.8%beta3-Adrenergic Agonist7.7%Myrbetriq100%Part D<11 patientsCholinergic Muscarinic Antagonist5.1%Oxybutynin Chloride Er100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
1 NIH research award on record, funded 2005–2009 per NIH RePORTER. The latest:
- Correlating Multiple Sclerosis Phenotypes with Genotypes
University of California, San Francisco
FY2009$161,406K23NS048869 - Correlating Multiple Sclerosis Phenotypes with Genotypes
University of California, San Francisco
FY2008$161,406K23NS048869 - Correlating Multiple Sclerosis Phenotypes with Genotypes
University of California, San Francisco
FY2007$161,406K23NS048869
Congress activity
Updated 14 Oct 2026
1 congress contribution (2024) across ASH per OpenAlex. The most recent:
- A Study of Kyv-101, a CD19 CAR T Cell Therapy, in Participants with Treatment Refractory Progressive Multiple Sclerosis
ASH Annual Meeting
ASH2024Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Efficacy of Inebilizumab in N-MOmentum Trial Participants With or Without Prior Immunosuppressants.
Annals of clinical and translational neurology
Article2026 - Diagnostic performance of central vein sign and paramagnetic rim lesion integration for multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England)
Article2026 - Development of a Diagnostic Autoantibody Assay to a Consensus Motif for the Risk Prediction of Epstein-Barr Virus-Related Multiple Sclerosis.
Neurology(R) neuroimmunology & neuroinflammation
Article2026 - Closing the referral gap: The role of a quality improvement initiative to enhance pelvic health physical therapy referrals for persons with multiple sclerosis-related bladder symptoms.
Multiple sclerosis journal - experimental, translational and clinical
Article2026
Most-cited works
by citation count (OpenAlex)- 01Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosisArticle2,753 citations2011
- 02Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosisArticle1,451 citations2013
- 03Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibilityArticle1,439 citations2019
- 04
- 05Treatment of Multiple Sclerosis: A ReviewArticle952 citations2020
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/bruce-cree-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
profiles.ucsf.edu/bruce.cree
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗ - ResearchGate
researchgate.net/profile/Bruce-Cree
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
- Board certified
Neurology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Editorial & leadership roles
journal and society appointments- Member
SRNA Medical Professional Network
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →wearesrna.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
- Fellow
American Academy of Neurology (FAAN)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →neurologylive.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
Media & interviews
press, podcasts and appearances- "Understanding Silent Progression in Multiple Sclerosis"
video interview, NeurologyLive
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →neurologylive.com ↗ - "Proven Therapies Underutilized in State of Care for NMOSD"
video interview, NeurologyLive
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →neurologylive.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cgtlive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Miller, MD
University of California, San Francisco (UCSF)
Gregory Marcus, MD
University of California, San Francisco (UCSF)
Eric Small, MD
University of California, San Francisco (UCSF)
Adam Boxer, MD
University of California, San Francisco (UCSF)
Bruce Miller, MD
University of California, San Francisco (UCSF)
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
Steven Dekosky, MD
University of Florida